Karen Firestone - Mar 16, 2023 Form 4 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role
Director
Signature
/s/ Joshua B. Cohen, as Attorney in Fact
Stock symbol
AMLX
Transactions as of
Mar 16, 2023
Transactions value $
$31,990
Form type
4
Date filed
3/20/2023, 08:22 PM
Next filing
Jun 12, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMLX Common Stock Purchase $32K +1K $31.99 1K Mar 16, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMLX Stock Option (Right to Buy) Award $0 +27.4K $0.00 27.4K Mar 16, 2023 Common Stock 27.4K $32.08 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.96 to $32.00. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request
F2 One-third of the shares subject to the option shall vest on the first anniversary of the date of grant, and the remaining two-thirds will vest in equal monthly installments over two years, provided, however, that all vesting shall cease if the director resigns from the Board or otherwise ceases to serve as a director of the Issuer.